MedTrace Logo

A Study of EBC-129 in Advanced Solid Tumours

NCT05701527 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 98

Last updated 2026-02-05

No results posted yet for this study

Summary

This study will assess the safety and tolerability of EBC-129 as a single agent and in combination with pembrolizumab in patients with advanced solid tumours

Conditions

  • Advanced Solid Tumours

Interventions

DRUG

EBC-129

EBC-129 will be administered on Day 1 of each 21-Day cycle (Parts A, B, and C), and two doses starting from Day 1 for 21-day cycle and three doses starting from Day 1 for 28-day cycle (Part D) via a 30-120-minute intravenous (IV) fusion.

DRUG

Pembrolizumab

Pembrolizumab will be administered at the dose of 200 mg IV every 21 days.

Sponsors & Collaborators

  • Parexel

    collaborator INDUSTRY

  • EDDC (Experimental Drug Development Centre), A*STAR Research Entities

    lead OTHER_GOV

Principal Investigators

  • Venkateshan Srirangam Prativadibhayankara, MD · EDDC (Experimental Drug Development Centre), A*STAR Research Entities

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-28
Primary Completion
2026-12-24
Completion
2026-12-24
FDA Drug
Yes

Countries

  • United States
  • Singapore
  • Taiwan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05701527 on ClinicalTrials.gov